Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

atai Life Sciences Applauds Breakthrough in Depression Treatment with Beckley Psytech’s DMT Study

Mar 27 • 3 min read

atai Life Sciences, trading under NASDAQ:ATAI and ETR:9VC, recently announced the encouraging findings from a study conducted by its investee, Beckley Psytech, on a pioneering DMT formulation, BPL-003, for individuals struggling with treatment-resistant depression. During this open-label Phase 2a investigation, a select group of patients received a single dose of BPL-003. This novel, synthetic formulation…

Insurance Coverages To Help Bring Psychedelic Treatments to Market

Mar 22 • 4 min read

The revitalization of psychedelic substances for therapeutic applications has ignited significant interest in their potential as breakthrough treatments, driving a flurry of research and efforts to introduce these therapies into the market. In the United States, the journey to market for regulated substances is stringent, requiring extensive research, clinical tests, and trials overseen by the…

Studying the Effects of Natural Psilocybin Versus Synthetic Versions

Mar 21 • 3 min read

Recent studies have shed light on the intriguing potential of hallucinogenic mushrooms, specifically those containing psilocybin, in offering therapeutic benefits for individuals suffering from anxiety, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorders (OCD). Spearheaded by Professor Bernard Lerer, this research delves into the realm of psychedelics as a promising avenue for treating psychiatric conditions that…

Psilocybin Study Reveals the Brain Suppresses Reactions To Angry Faces

Mar 21 • 3 min read

Recent studies have unearthed fascinating insights into how psilocybin, a naturally occurring compound in certain mushroom species—often referred to as magic mushrooms—affects the brain, particularly the amygdala. The amygdala plays a crucial role in how we process emotions, especially those related to fear and anxiety, by linking these emotions to our senses, memories, and learning…

Gilgamesh Receives Grant To Combat Opioid Dependency

Mar 20 • 2 min read

Gilgamesh Pharmaceuticals, located in New York, has recently received a significant financial boost with a $14 million grant from the National Institute on Drug Abuse (NIDA). This funding is set to propel the development of GM-3009, a novel substance engineered as a safer substitute to ibogaine, aiming to revolutionize the treatment of substance use disorders,…

Pages: 1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253